• Policy
• “Bio-vaccine fund will be created within the year”
• by Lee, Jeong-Hwan Aug 22, 2022 05:53am

• Policy
• The PVA exception to COVID-19 cold drug is actively applied
• by Lee, Tak-Sun Aug 22, 2022 05:52am

• Policy
• Manufacturing for development allowed during suspensions
• by Lee, Hye-Kyung Aug 19, 2022 05:53am

• Policy
• We need to increase the rate of PO tx for COVID-19 crisis
• by Lee, Jeong-Hwan Aug 19, 2022 05:53am

• Policy
• KDCA opposes use of Paxlovid in healthy 50s
• by Lee, Jeong-Hwan Aug 18, 2022 05:48am

• Policy
• Why is price different btw patent-expired original/generic
• by Lee, Tak-Sun Aug 18, 2022 05:47am

• Policy
• KDCA will announce its plan to inoculate bivalent vaccine
• by Lee, Jeong-Hwan Aug 17, 2022 05:52am

• Policy
• Novavax vaccine approved for use for 12+ years in Korea
• by Lee, Hye-Kyung Aug 17, 2022 05:52am

• Policy
• Generic exclusivity of Ticagrelor terminated but no benefits
• by Lee, Tak-Sun Aug 16, 2022 05:47am

• Policy
• Why AZ’s vaccine was used as comparator for SKY Covione
• by Lee, Hye-Kyung Aug 16, 2022 05:46am